Could Endocan, a Marker of Inflammation and Endothelial Dysfunction, be a New Diagnostic Marker for Fibromyalgia?

MERTOĞLU C., Gunay M., Yerligok O.

CLINICAL LABORATORY, vol.64, no.3, pp.405-410, 2018 (SCI-Expanded, Scopus) identifier identifier

  • Publication Type: Article / Article
  • Volume: 64 Issue: 3
  • Publication Date: 2018
  • Doi Number: 10.7754/clin.lab.2017.171024
  • Journal Name: CLINICAL LABORATORY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.405-410
  • Keywords: Endocan [endothelial cell-specific molecule-1 (ESM-1)], fibromyalgia, inflammation, endothelial dysfunction, RHEUMATOLOGY 1990 CRITERIA, CYTOKINES, SERUM, CLASSIFICATION, DISEASE, ESM-1, IL-6
  • Inonu University Affiliated: No

Abstract

Background: Although the pathophysiology of fibromyalgia has not yet been fully clarified, inflammation and endothelial dysfunction have been suggested to occur in patients with fibromyalgia. In recent years, endocan has been reported as an important biomarker for inflammation and endothelial dysfunction. In this study, we investigated this mechanism by measuring the serum endocan levels in fibromyalgia patients.